In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Changing Dynamics of Cancer Drug Development

Executive Summary

The growing number and size of oncology players has made the field far more competitive, eroding--or at least, shifting--some of the advantages that continue to attract smaller firms to the field.

You may also be interested in...



Cancer Stem Cells: A New Approach to Treating Cancer

Cancer stem cells are a hot, promising new approach to treating cancer--one which may not only prevent cancer from spreading, but also help diagnose and even cure the disease. Start-ups are beginning to emerge, and so is investor interest.

Early Rewards for Careful Targeting in Oncology

Two early-stage cancer deals at the end of last year set a new high for European biotech pre-clinical deal dollars. They also highlighted the growing value, to Big Pharma and Big Biotech, of targeted, well-designed oncology leads, as progress in cancer therapeutics raises the hurdles for new products' potency and selectivity.

Early Rewards for Careful Targeting in Oncology

Two early-stage cancer deals at the end of last year set a new high for European biotech pre-clinical deal dollars. They also highlighted the growing value, to Big Pharma and Big Biotech, of targeted, well-designed oncology leads, as progress in cancer therapeutics raises the hurdles for new products' potency and selectivity.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

IV002671

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel